Post-COVID Syndrome and Tachycardia: Theoretical Base and Treatment Experience
Open Access
- 7 May 2021
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (2), 256-262
- https://doi.org/10.20996/1819-6446-2021-04-08
Abstract
The coronavirus pandemic showed not only an increase in levels of excess morbidity and mortality in the acute phase, but also persisting symptoms 4 weeks after the onset of the disease. A review of international studies on the prevalence and diversity of the manifestations of postcoid syndrome is presented. The data on such a manifestation of post-COVID syndrome as postural orthostatic tachycardia syndrome (POTS) are accumulating. Pathogenetic mechanisms, modern diagnostic criteria and research data on the prevalence of this syndrome are presented in the article. The Canadian Cardiovascular Society has proposed medications as a treatment for POTS, including the sinus node If channel inhibitor ivabradine. Data from several studies showing the effectiveness of this drug for POTS, including after suffering COVID-19, are presented in the article. Clinical data on the prevalence of tachycardia among patients admitted to the Sechenov University hospital are presented. About 18% of patients with hypertension and 21% of patients with normal blood pressure had a high heart rate. A clinical example of the use of ivabradine in a patient after a coronavirus infection is presented. Drug interactions and individual tolerance of ivabradine in patients after coronavirus infection are being discussed. The authors put forward the hypothesis about the further prospect of using ivabradine in the treatment of clinical manifestations of postcoid syndrome on the basis of literature data and their own experience.Keywords
This publication has 31 references indexed in Scilit:
- Depression as a Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome SurvivorsPsychiatry Investigation, 2019
- Autoimmunity in postural orthostatic tachycardia syndrome: Current understandingAutonomic Neuroscience, 2018
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Ivabradine in Postural Orthostatic Tachycardia Syndrome: Preliminary Experience in ChildrenAmerican Journal of Cardiovascular Drugs, 2017
- Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experiencePacing and Clinical Electrophysiology, 2017
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome PatientsRambam Maimonides Medical Journal, 2015
- Ivabradine in treatment of sinus tachycardia mediated vasovagal syncopeEP Europace, 2013
- Single centre experience of ivabradine in postural orthostatic tachycardia syndromeEP Europace, 2010
- Stress and Psychological Distress among SARS Survivors 1 Year after the OutbreakThe Canadian Journal of Psychiatry, 2007